The vaccine is targeted at individuals between the ages of 4 and 60, with a particular focus on high-risk groups such as schoolchildren, people who have previously contracted dengue, and elderly individuals. Healthcare providers have reported a significant increase in inquiries about the vaccine, especially from parents and those concerned about the upcoming dengue season.